LLY
2025Q2BMOEli Lilly and Company primary · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
Street
Consensus EPS5.61
Consensus rev—
EPS high—
EPS low—
Dispersion—
Analysts—
EPS rev net 7d—
EPS rev net 30d—
Consensus Δ 7d—
Consensus Δ 30d—
Options
Implied move3.2%
IV front—
P/C full—
P/C front—
Features as of2025-08-06
Run-up
Close—
Ret 5d-1.8%
Ret 10d-6.6%
Ret 20d-5.2%
Ret 30d-4.1%
Actual EPS
6.31Beat
Estimated EPS5.61
Actual revenue
15.6B
Surprise %+12.5%
Beat / missBeat
Beat streak 41
Beat streak 81
Reaction
1-day stock reaction-5.2%
Implied vs actual
Implied 3.2%Actual 9.5%
Gap reaction-9.5%
Day result-14.1%
Next-day upNo
Realized / IV2.97×
Post tape
Post 5d+6.8%
Post 10d+10.8%
Post volume26.1M
Vol ×10d6.19×
Vol ×20d7.08×
Post range6.7%